Value of systemic immune inflammation index in predicting the efficacy of first-line chemotherapy and survival outcome in patients with HER2 negative advanced gastric cancer

ZHOU Yangyang; LIU Jing; ZHU Yeqing; YANG Yan; ZHOU Zhengguang; WANG Mingxi

doi:10.16766/j.cnki.issn.1674-4152.003283

Volume 21 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2023 > 21(12): 2031-2035

ZHOU Yangyang, LIU Jing, ZHU Yeqing, YANG Yan, ZHOU Zhengguang, WANG Mingxi. Value of systemic immune inflammation index in predicting the efficacy of first-line chemotherapy and survival outcome in patients with HER2 negative advanced gastric cancer[J]. Chinese Journal of General Practice, 2023, 21(12): 2031-2035. doi: 10.16766/j.cnki.issn.1674-4152.003283

Citation:

ZHOU Yangyang, LIU Jing, ZHU Yeqing, YANG Yan, ZHOU Zhengguang, WANG Mingxi. Value of systemic immune inflammation index in predicting the efficacy of first-line chemotherapy and survival outcome in patients with HER2 negative advanced gastric cancer[J]. Chinese Journal of General Practice, 2023, 21(12): 2031-2035. doi: 10.16766/j.cnki.issn.1674-4152.003283

Citation:

ZHOU Yangyang, LIU Jing, ZHU Yeqing, YANG Yan, ZHOU Zhengguang, WANG Mingxi. Value of systemic immune inflammation index in predicting the efficacy of first-line chemotherapy and survival outcome in patients with HER2 negative advanced gastric cancer[J]. Chinese Journal of General Practice, 2023, 21(12): 2031-2035. doi: 10.16766/j.cnki.issn.1674-4152.003283

PDF( 616 KB)

Value of systemic immune inflammation index in predicting the efficacy of first-line chemotherapy and survival outcome in patients with HER2 negative advanced gastric cancer

doi: 10.16766/j.cnki.issn.1674-4152.003283

1.
Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

AHWJ2022a010

S202110367134

2021byzd110

Received Date: 2023-04-12
Available Online: 2024-01-29

Abstract

Abstract

Objective To explore the value of the systemic immune-inflammatory index (SII) in predicting the efficacy of first-line chemotherapy and survival in patients with human epidermal growth factor receptor 2 (HER2) negative advanced gastric cancer. Methods The clinical data of advanced gastric cancer patients who received standard first-line chemotherapy at the Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical College from February 2017 to June 2021 were retrospectively collected. The SII values were calculated based on the results of the baseline routine blood test. The receiver operating characteristic (ROC) curve and X-tile software were used to determine the optimal cut off value of SII for therapeutic effect and prognosis, and patients was classified into high and low SII groups. The relationship between SII and clinicopathological characteristics, efficacy of first-line chemotherapy, progression-free survival (PFS) and overall survival (OS) of patients with advanced gastric cancer was analyzed. Results A total of 90 patients with advanced gastric cancer were enrolled. The objective response rates of patients in the high and low SII groups were 3.45% (1/29) and 19.67% (12/61), and the disease control rates were 41.38% (12/29) and 77.05% (47/61), respectively; patients with lower baseline SII had better chemotherapy efficacy (χ²=11.075, P=0.001). The mPFS of patients in the low SII group was significantly longer than that of patients in the high SII group (4.57 months vs. 2.13 months, P<0.001), and patients with low SII achieved a longer OS than patients with high SII (9.83 months vs. 3.97 months, P<0.001). The results of univariate and multivariate Cox analysis showed that the level of baseline SII was an independent prognostic factor affecting PFS and OS of first-line therapy in patients with advanced gastric cancer. Conclusion The baseline level of SII has potential value in predicting the efficacy and prognosis of first-line chemotherapy in patients with advanced gastric cancer, and patients with high SII tend to have poor efficacy and prognosis.
- Advanced gastric cancer,
- Systemic immune inflammation index,
- Efficacy,
- Prognosis

FullText(HTML)

References(19)

References

[1]	XIA C, DONG X, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5): 584-590. doi: 10.1097/CM9.0000000000002108
[2]	SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648. doi: 10.1016/S0140-6736(20)31288-5
[3]	常睿敏, 杨阳, 刘宝瑞. 胃癌免疫治疗研究进展[J]. 中国临床研究, 2023, 36(2): 161-165. CHANG R M, YANG Y, LIU B R. Advances in immunotherapy for gastric cancer[J]. Chinese Journal of Clinical Research, 2023, 36(2): 161-165.
[4]	李莹, 杨波, 张競. 4种炎症指标对ⅠA2~ⅡA2期宫颈癌预后的预测价值[J]. 中华全科医学, 2021, 19(4): 554-557, 576. doi: 10.16766/j.cnki.issn.1674-4152.001859 LI Y, YANG B, ZHANG J. The prognostic value of SII, NLR, PLR and LMR in the stage ofⅠA-ⅡA2 cervical cancer[J]. Chinese Journal of General Practice, 2021, 19(4): 554-557, 576. doi: 10.16766/j.cnki.issn.1674-4152.001859
[5]	SUN L, LIANG H, FENG Y. Comment on "high systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma"[J]. Ann Surg, 2021, 274(6): e668-e669.
[6]	GRETEN F R, GRIVENNIKOV S I. Inflammation and cancer: triggers, mechanisms, and consequences[J]. Immunity, 2019, 51(1): 27-41. doi: 10.1016/j.immuni.2019.06.025
[7]	SCHOBERT I T, SAVIC L J, CHAPIRO J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE[J]. Eur Radiol, 2020, 30(10): 5663-5673. doi: 10.1007/s00330-020-06931-5
[8]	SHIMIZU T, TANIGUCHI K, ASAKUMA M, et al. Lymphocyte-to-monocyte ratio and prognostic nutritional index predict poor prognosis in patients on chemotherapy for unresectable pancreatic cancer[J]. Anticancer Res, 2019, 39(4): 2169-2176. doi: 10.21873/anticanres.13331
[9]	HUANG H, LIU Q, ZHU L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer[J]. Sci Rep, 2019, 9(1): 3284. doi: 10.1038/s41598-019-39150-0
[10]	LIU J, LI S, ZHANG S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J]. J Clin Lab Anal, 2019, 33(8): e22964. DOI: 10.1002/jcla.22964.
[11]	ZHU Z, CONG X, LI R, et al. Preoperative systemic immune-inflammation index (SII) for predicting the survival of patients with stage Ⅰ-Ⅲ gastric cancer with a signet-ring cell (SRC) component[J]. Biomed Res Int, 2020, 2020: 5038217. DOI: 10.1155/2020/5038217.
[12]	YIN C, GAO B, YANG J, et al. Glucose transporter-1 (GLUT-1) expression is associated with tumor size and poor prognosis in locally advanced gastric cancer[J]. Med Sci Monit Basic Res, 2020, 26: e920778. DOI: 10.12659/MSMBR.920778.
[13]	ALSHEHRI A, ALANEZI H, KIM B S. Prognosis factors of advanced gastric cancer according to sex and age[J]. World J Clin Cases, 2020, 8(9): 1608-1619. doi: 10.12998/wjcc.v8.i9.1608
[14]	WANG W, TONG Y, SUN S, et al. Predictive value of NLR and PLR in response to preoperative chemotherapy and prognosis in locally advanced gastric cancer[J]. Front Oncol, 2022, 12: 936206. DOI: 10.3389/fonc.2022.936206.
[15]	WANG S B, CHEN J Y, XU C, et al. Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection[J]. Front Oncol, 2022, 12: 1040495. DOI: 10.3389/fonc.2022.1040495.
[16]	XU Z J, CHEN X B, AN J, et al. Correlation analysis between preoperative systemic immune inflammation index and prognosis of patients after radical gastric cancer surgery: based on propensity score matching method[J]. World J Surg Oncol, 2022, 20(1): 1. doi: 10.1186/s12957-021-02457-2
[17]	DING P, GUO H, SUN C, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study[J]. BMC Gastroenterol, 2022, 22(1): 121. doi: 10.1186/s12876-022-02199-9
[18]	CHO U, PARK H S, IM S Y, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer[J]. PLoS One, 2018, 13(7): e0200936. DOI: 10.1371/journal.pone.0200936.
[19]	WANG H, YIN X, MA K, et al. Nomogram based on preoperative fibrinogen and systemic immune-inflammation index predicting recurrence and prognosis of patients with Borrmann type Ⅲ advanced gastric cancer[J]. J Inflamm Res, 2023, 16: 1059-1075. doi: 10.2147/JIR.S404585

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(7)

Get Citation

PDF

XML

Article Metrics

Article views (191) PDF downloads(9)

Value of systemic immune inflammation index in predicting the efficacy of first-line chemotherapy and survival outcome in patients with HER2 negative advanced gastric cancer

doi: 10.16766/j.cnki.issn.1674-4152.003283

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Value of systemic immune inflammation index in predicting the efficacy of first-line chemotherapy and survival outcome in patients with HER2 negative advanced gastric cancer

doi: 10.16766/j.cnki.issn.1674-4152.003283

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content